Ionis Pharmaceuticals, Inc.

Equities

IONS

US4622221004

Market Closed - Nasdaq Other stock markets 01:30:00 14/03/2026 am IST			5-day change	1st Jan Change
71.19 ^USD	-1.59%		-3.85%	-10.01%

12/03	Biogen Inc. Presents Additional Salanersen Data and Debuts Phase 3 Clinical Trial Program	CI
12/03	Ionis Pharmaceuticals, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 01:30 PM

Transcript : Ionis Pharmaceuticals, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 08

Published on 01/14/2026 at 12:35 am IST

S&P Capital IQ

Presenter Speech
Jessica Fye (Analysts)

Great. Good morning, everyone. Welcome. My name is Jess Fye, large-cap biotech analyst at JPMorgan, and we're continuing the 44th Annual Healthcare Conference

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Ionis Pharmaceuticals, Inc.

12/03	Biogen Inc. Presents Additional Salanersen Data and Debuts Phase 3 Clinical Trial Program	CI
12/03	Ionis Pharmaceuticals, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 01:30 PM
10/03	Ionis Pharmaceuticals, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 03:40 PM
09/03	Ionis Pharmaceuticals, Inc. Announces Board Changes, Effective June 4, 2026	CI
06/03	Ionis Pharmaceuticals Insider Sold Shares Worth $1,696,181, According to a Recent SEC Filing	MT
06/03	Ionis Pharmaceuticals Insider Sold Shares Worth $4,354,428, According to a Recent SEC Filing	MT
05/03	Biogen Inc Announces to Present New Data and Updates from Its Spinal Muscle Atrophy Research Programs	CI
02/03	Ionis Pharmaceuticals, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 10:30 AM
27/02	Ionis Pharmaceuticals, Inc. Announces to Present New Data Supporting Dawnzera (Donidalorsen) in Hereditary Angioedema At 2026 Aaaai Annual Meeting	CI
27/02	Olezarsen sNDA accepted by the FDA for Priority Review	RE
26/02	Ionis Pharmaceuticals, Inc. Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference, Feb-26-2026 12:00 PM
26/02	Ionis Pharmaceuticals, Inc. Announces That the U.S. Food and Drug Administration Accepts for Priority Review the Supplemental New Drug Application for Olezarsen for Severe Hypertriglyceridemia	CI
26/02	GSK moves towards clearance of two new drugs in China and Japan	AN
25/02	Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
25/02	Ionis Pharmaceuticals, Inc., Q4 2025 Earnings Call, Feb 25, 2026